Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

  • Comabella Lopez, Manuel
  • TUR, CARMEN
  • Arrambide, Georgina
Fluid biomarkers; Artificial intelligence; Multiple scleorsis, Biomarcadores de fluidos; Inteligencia artificial; Esclerosis múltiple, Biomarcadors de fluids; Intel·ligència artificial; Esclerosi múltiple, Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CT is currently being funded by the Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (award number: CP23/00117). She has also received research support from the ISCIII through the FORTALECE grant (FORT23/00034).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A data-driven model of disability progression in progressive multiple sclerosis

  • garbarino, sara
  • Lorenzi, Marco
  • Pardini, Matteo
  • PIANA, MICHELE
  • UCCELLI, Antonio
  • TUR, CARMEN
Bayesian learning; Multimodal data; Primary progressive multiple sclerosis, Aprendizaje bayesiano; Datos multimodales; Esclerosis múltiple progresiva primaria, Aprenentatge bayesià; Dades multimodals; Esclerosi múltiple progressiva primària, This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume. From these data, Gaussian process progression model infers a data-driven description of the progression common to all individuals, alongside scores measuring the individual progression rates relative to the population, spanning ∼50 years of disease duration. Along this timeline, Gaussian process progression model identifies an initial steep worsening of the expanded disability status scale that stabilizes after ∼30 years of disease duration, suggesting its diminished utility in monitoring disease progression beyond this time. Conversely, it underscores the slower evolution of normalized brain volume across the disease duration. The individual progression rates estimated by Gaussian process progression model can be used to identify three distinct sub-groups within the primary progressive multiple sclerosis population: a normative group (76% of the population) and two ‘outlier’ sub-groups displaying either accelerated (13% of the population) or decelerated (11%) progression compared to the normative one. Notably, fast progressors exhibit older age at symptom onset (38.5 versus 35.0, P < 0.0001), a higher prevalence of males (61.1% versus 48.5%, P = 0.013) and a higher lesion volumes both in T1 (4.1 versus 0.6, P < 0.0001) and T2 (16.5 versus 7.9, P < 0.0001) compared to slow progressors. Prognostically, fast progressors demonstrate a significantly worse prognosis, with double the risk of experiencing a 3-month confirmed disease progression on expanded disability status scale compared to the normative population according to Cox proportional hazard modelling (HR = 2.09, 95% CI: 1.66–2.62, P < 0.0001) and a shorter median time from the onset of disease symptoms to reaching a confirmed expanded disability status scale 6 (95% CI: 5.83–7.68 years, P < 0.0001). External validation on a test set comprising 227 primary progressive multiple sclerosis participants from the SPI2 trial produced consistent results, with slow progressors exhibiting a reduced risk of experiencing 3-month confirmed disease progression determined through expanded disability status scale (HR = 0.21), while fast progressors facing an increased risk (HR = 1.45). This study contributes to our understanding of disability accrual in primary progressive multiple sclerosis, integrating diverse disability assessments and MRI measurements. Moreover, the identification of distinct sub-groups underscores the heterogeneity in progression rates among patients, offering invaluable insights for patient stratification and monitoring in clinical trials, potentially facilitating more targeted and personalized interventions., This investigation was supported by an award from the International Progressive Multiple Sclerosis Alliance (award reference number PA-1412-02420). This work was supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministero dell’Università e delle Ricerca, Italy (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). The authors acknowledge financial contribution from the Italian Ministry of Health, with the project NeuroArtP3 (NET-2018-12366666). S.G. acknowledges financial contributions from the Istituto Nazionale di Alta Matematica—Gruppo Nazionale di Calcolo Scientifico (INdAM–GNCS) Project (CUP_E53C22001930001). C.T. is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). She has also received a 2023 FORTALECE grant, awarded by the ISCIII (FORT23/00034) and a 2020 Junior Leader La Caixa Fellowship (fellowship code: LCF/BQ/PI20/11760008), awarded by ‘la Caixa’ Foundation (ID 100010434), a 2021 Merck’s Award for the Investigation in multiple sclerosis, awarded by Fundación Merck Salud (Spain), and a Research Grant awarded by the ISCIII, Ministerio de Ciencia e Innovación de España (PI21/01860). M.L. acknowledges funding from the Michael J. Fox Foundation for Parkinson’s Research (grant ID MJFF-021683). F.B. received the 2022 Biostatistic/Informatics Junior Faculty Award (grant code BI-2107-38160) awarded by the National Multiple Sclerosis Society.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluation of magnetic resonance spectroscopy total sodium concentration measures, and associations with microstructure and physical impairment in cervical myelopathy

  • Solanky, Bhavana
  • Al-Ahmad, Selma
  • Yang, Xixi
  • Prados Carrasco, Ferran
  • TUR, CARMEN
  • Grussu, Francesco
Cervical myelopathy; Macromolecular tissue volume; Spinal cord, Mielopatia cervical; Volum del teixit macromolecular; Medul·la espinal, Mielopatía cervical; Volumen del tejido macromolecular; Médula espinal, Spinal cord injury causes a cascade of physiological responses, which may trigger a subsequent neurotoxic increase in intracellular sodium. This can lead to neurodegeneration, both at and beyond the site of injury, causing clinical symptoms and loss of function. However, in vivo measurements of tissue sodium remain challenging. Here we utilise sodium magnetic resonance spectroscopy (23Na-MRS) at 3T to measure tissue sodium concentration (TSC) and its association with microstructural measures and macromolecular MRI metrics in the cervical spinal cord, distal to the site of injury. Twenty people with cervical myelopathy and twenty healthy controls, were studied. Associations with motor and sensory impairments were explored using ASIA and jOAMEQ scores. No significant difference in TSC in the cervical myelopathy group (39 ± 10 mM) relative to healthy controls (35 ± 13 mM) was found. However, patients had a significantly lower cord-cross-sectional area than controls (70 ± 9 mm2 vs. 82 ± 9 mm2, p < 0.001). Lower-extremity function positively correlated with intracellular volume fraction (p = 0.031). In conclusion, using 23Na-MRS, TSC in cervical myelopathy patients was successfully measured. Differences in TSC relative to healthy controls did not reach significance, despite a significant reduction in cord-cross-sectional area. However, lower intracellular volume fraction, indicating reduced neurite density distal to the site of injury, was associated with physical impairment., This study was supported by Wings for Life (#169111) to CGWK and BS. CGWK receives funding from MRC (#MR/S026088/1), Ataxia UK, Rosetrees Trust (#PGL22/100041 and #PGL21/10079). JNP is supported in part by funding from the United Kingdom’s Department of Health NIHR University College London Hospitals Biomedical Research Centres funding scheme. BS is also supported by the Multiple Sclerosis Society (175). CT is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). FG receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010".
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

  • Comabella Lopez, Manuel
  • TUR, CARMEN
  • Arrambide, Georgina
Fluid biomarkers; Artificial intelligence; Multiple scleorsis, Biomarcadores de fluidos; Inteligencia artificial; Esclerosis múltiple, Biomarcadors de fluids; Intel·ligència artificial; Esclerosi múltiple, Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CT is currently being funded by the Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (award number: CP23/00117). She has also received research support from the ISCIII through the FORTALECE grant (FORT23/00034).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A data-driven model of disability progression in progressive multiple sclerosis

  • garbarino, sara
  • Lorenzi, Marco
  • Pardini, Matteo
  • PIANA, MICHELE
  • UCCELLI, Antonio
  • TUR, CARMEN
Bayesian learning; Multimodal data; Primary progressive multiple sclerosis, Aprendizaje bayesiano; Datos multimodales; Esclerosis múltiple progresiva primaria, Aprenentatge bayesià; Dades multimodals; Esclerosi múltiple progressiva primària, This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume. From these data, Gaussian process progression model infers a data-driven description of the progression common to all individuals, alongside scores measuring the individual progression rates relative to the population, spanning ∼50 years of disease duration. Along this timeline, Gaussian process progression model identifies an initial steep worsening of the expanded disability status scale that stabilizes after ∼30 years of disease duration, suggesting its diminished utility in monitoring disease progression beyond this time. Conversely, it underscores the slower evolution of normalized brain volume across the disease duration. The individual progression rates estimated by Gaussian process progression model can be used to identify three distinct sub-groups within the primary progressive multiple sclerosis population: a normative group (76% of the population) and two ‘outlier’ sub-groups displaying either accelerated (13% of the population) or decelerated (11%) progression compared to the normative one. Notably, fast progressors exhibit older age at symptom onset (38.5 versus 35.0, P < 0.0001), a higher prevalence of males (61.1% versus 48.5%, P = 0.013) and a higher lesion volumes both in T1 (4.1 versus 0.6, P < 0.0001) and T2 (16.5 versus 7.9, P < 0.0001) compared to slow progressors. Prognostically, fast progressors demonstrate a significantly worse prognosis, with double the risk of experiencing a 3-month confirmed disease progression on expanded disability status scale compared to the normative population according to Cox proportional hazard modelling (HR = 2.09, 95% CI: 1.66–2.62, P < 0.0001) and a shorter median time from the onset of disease symptoms to reaching a confirmed expanded disability status scale 6 (95% CI: 5.83–7.68 years, P < 0.0001). External validation on a test set comprising 227 primary progressive multiple sclerosis participants from the SPI2 trial produced consistent results, with slow progressors exhibiting a reduced risk of experiencing 3-month confirmed disease progression determined through expanded disability status scale (HR = 0.21), while fast progressors facing an increased risk (HR = 1.45). This study contributes to our understanding of disability accrual in primary progressive multiple sclerosis, integrating diverse disability assessments and MRI measurements. Moreover, the identification of distinct sub-groups underscores the heterogeneity in progression rates among patients, offering invaluable insights for patient stratification and monitoring in clinical trials, potentially facilitating more targeted and personalized interventions., This investigation was supported by an award from the International Progressive Multiple Sclerosis Alliance (award reference number PA-1412-02420). This work was supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministero dell’Università e delle Ricerca, Italy (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). The authors acknowledge financial contribution from the Italian Ministry of Health, with the project NeuroArtP3 (NET-2018-12366666). S.G. acknowledges financial contributions from the Istituto Nazionale di Alta Matematica—Gruppo Nazionale di Calcolo Scientifico (INdAM–GNCS) Project (CUP_E53C22001930001). C.T. is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). She has also received a 2023 FORTALECE grant, awarded by the ISCIII (FORT23/00034) and a 2020 Junior Leader La Caixa Fellowship (fellowship code: LCF/BQ/PI20/11760008), awarded by ‘la Caixa’ Foundation (ID 100010434), a 2021 Merck’s Award for the Investigation in multiple sclerosis, awarded by Fundación Merck Salud (Spain), and a Research Grant awarded by the ISCIII, Ministerio de Ciencia e Innovación de España (PI21/01860). M.L. acknowledges funding from the Michael J. Fox Foundation for Parkinson’s Research (grant ID MJFF-021683). F.B. received the 2022 Biostatistic/Informatics Junior Faculty Award (grant code BI-2107-38160) awarded by the National Multiple Sclerosis Society.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evaluation of magnetic resonance spectroscopy total sodium concentration measures, and associations with microstructure and physical impairment in cervical myelopathy

  • Solanky, Bhavana
  • Al-Ahmad, Selma
  • Yang, Xixi
  • Prados Carrasco, Ferran
  • TUR, CARMEN
  • Grussu, Francesco
Cervical myelopathy; Macromolecular tissue volume; Spinal cord, Mielopatia cervical; Volum del teixit macromolecular; Medul·la espinal, Mielopatía cervical; Volumen del tejido macromolecular; Médula espinal, Spinal cord injury causes a cascade of physiological responses, which may trigger a subsequent neurotoxic increase in intracellular sodium. This can lead to neurodegeneration, both at and beyond the site of injury, causing clinical symptoms and loss of function. However, in vivo measurements of tissue sodium remain challenging. Here we utilise sodium magnetic resonance spectroscopy (23Na-MRS) at 3T to measure tissue sodium concentration (TSC) and its association with microstructural measures and macromolecular MRI metrics in the cervical spinal cord, distal to the site of injury. Twenty people with cervical myelopathy and twenty healthy controls, were studied. Associations with motor and sensory impairments were explored using ASIA and jOAMEQ scores. No significant difference in TSC in the cervical myelopathy group (39 ± 10 mM) relative to healthy controls (35 ± 13 mM) was found. However, patients had a significantly lower cord-cross-sectional area than controls (70 ± 9 mm2 vs. 82 ± 9 mm2, p < 0.001). Lower-extremity function positively correlated with intracellular volume fraction (p = 0.031). In conclusion, using 23Na-MRS, TSC in cervical myelopathy patients was successfully measured. Differences in TSC relative to healthy controls did not reach significance, despite a significant reduction in cord-cross-sectional area. However, lower intracellular volume fraction, indicating reduced neurite density distal to the site of injury, was associated with physical impairment., This study was supported by Wings for Life (#169111) to CGWK and BS. CGWK receives funding from MRC (#MR/S026088/1), Ataxia UK, Rosetrees Trust (#PGL22/100041 and #PGL21/10079). JNP is supported in part by funding from the United Kingdom’s Department of Health NIHR University College London Hospitals Biomedical Research Centres funding scheme. BS is also supported by the Multiple Sclerosis Society (175). CT is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). FG receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010".